Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.46 |
| ▸ | HTR1D | P28221 | 12/20 | 0.46 |
| ▸ | HTR1B | P28222 | 12/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.41 |
| ▸ | NMT1 | P30419 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349149 | 0.86 | UTS2R (0.45) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL5346023 | 0.81 | NMT1 (0.48) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL5352188 | 0.77 | HTR1A (0.43) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL5342124 | 0.72 | HTR1A (0.74) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL5342149 | 0.72 | HTR1A (0.59) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL4169835 | 0.71 | HTR1A (0.47) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL1339079 | 0.70 | SLC6A4 (0.41) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL31133320 | 0.70 | SLC6A4 (0.41) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL7288897 | 0.69 | SLC6A4 (0.40) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL6177917 | 0.68 | CYP2C9 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214674-B2 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20050153974-A1 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1480974-A1 | HETEROCYCLYLMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068771-A1 | HETEROCYCLYMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153974-A1 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | HTR1A, HTR1D, HTR2C | HTR1A 1/4885HTR1D 2/4885HTR1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.